tradingkey.logo

Milestone Pharmaceuticals Submits Response To The FDA’s CRL For CARDAMYST (Etripamil) Nasal Spray For PSVT Following Type A Meeting

ReutersJun 16, 2025 12:05 PM

- Milestone Pharmaceuticals Inc MIST.O:

  • MILESTONE PHARMACEUTICALS SUBMITS RESPONSE TO THE FDA’S CRL FOR CARDAMYST (ETRIPAMIL) NASAL SPRAY FOR PSVT FOLLOWING TYPE A MEETING

  • MILESTONE PHARMACEUTICALS INC - FDA TO DETERMINE ACCEPTANCE OF RESPONSE AND PDUFA DATE WITHIN 30 DAYS

  • MILESTONE PHARMACEUTICALS INC - REVIEW TIME EXPECTED TO BE WITHIN 2 OR 6 MONTHS FROM RESUBMISSION

  • MILESTONE PHARMACEUTICALS INC: BELIEVE TYPE A MEETING WITH FDA PROVIDED GUIDANCE TO SUBMIT RESPONSE TO CRL DIRECTLY AFTER MEETING

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI